Everon develops dual blood filtration for children with sepsis and expands into thirty countries

When conventional antibiotics fail to curb the excessive immune response in children, the acute inflammation known as sepsis becomes a direct race against time. This condition claims about three million children under five each year worldwide, after drugs alone cannot protect vital organs from rapid collapse.The violent immune response ignites a unquenchable fire inside the body with ordinary drugs, necessitating mechanical blood filtration to remove lethal toxins.

At this critical juncture, Everon steps in, having been selected among the top hundred startups in the Startup Battlefield competition at the Tech Crunch Disrupt 2026 conference, with a medical device aimed at lowering organ failure rates and speeding pediatric recovery. Co-founder and CEO Dima Romashin likens what happens in the patient’s body to a raging fire: internal toxins are the flames, while cytokines are the thick smoke rising. Unlike commercially available devices, the company has developed a mechanism that can absorb both elements simultaneously, treating flame and smoke together before it’s too late.

Although the company produces absorbers for adults, its Everon New device for small children has shown particular efficacy in intensive care settings. Romashin explains that children have a much smaller circulating blood volume than adults, making the transfer of adult technologies physiologically unsuitable and requiring finely engineered medical devices that match the specific characteristics of their small bodies. In April, the device received the European CE mark, the EU equivalent of U.S. FDA approval, becoming the first multi-mode blood purification device fully dedicated to pediatric sepsis cases.

The technique’s origins trace back to research led by scientists at Moscow State University, including co-founder Ivan Besonov, before Romashin, a serial entrepreneur, joined the executive team earlier this year to accelerate its commercial launch.The technology is now used in intensive care units across thirty countries, including European hospitals, Saudi Arabia and Thailand.The company is currently preparing to apply for U.S. FDA approval, while pursuing a path to reach two million dollars in annual revenue by the end of 2026.

The device’s entry into Saudi intensive care units shifts the regional discussion from purchasing adult machines and modifying them locally to directly investing in blood-purification platforms designed for children’s physiology.For medical leaders and supply-chain managers in Gulf and Arab-east hospitals, this development mandates a review of emergency-intervention protocols for pediatric septic shock. Relying on antibiotics alone is no longer sufficient in deteriorating cases, and providing precise purification devices that match infant blood volume requires specialized nursing training and a update to clinical procurement standards to avoid the risk of organ failure before complications proliferate.

Romashin acknowledges that his company does not grow at the breakneck pace typical of software and AI startups, but stresses that the true metric of success in biomedical technologies fundamentally differs from digital platform benchmarks. Growth here is not measured by cloud-usage rates, but by each child who survives organ failure and returns home unharmed.